Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Santhera Pharmaceuticals Holding AG    SANN   CH0027148649

SANTHERA PHARMACEUTICALS HOLDING AG

(SANN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
11/25/2020 11/26/2020 11/27/2020 11/30/2020 12/01/2020 Date
2.885(c) 2.9(c) 2.915(c) 2.93(c) 2.99 Last
97 552 46 555 46 159 58 431 48 157 Volume
+2.30% +0.52% +0.52% +0.51% +2.05% Change
More quotes
Financials
Sales 2020 15,3 M 16,9 M 16,9 M
Net income 2020 -56,5 M -62,8 M -62,8 M
Net Debt 2020 - - -
P/E ratio 2020 -1,00x
Yield 2020 -
Sales 2021 15,0 M 16,7 M 16,7 M
Net income 2021 -34,9 M -38,8 M -38,8 M
Net cash position 2021 6,00  6,67  6,67 
P/E ratio 2021 -2,77x
Yield 2021 -
Capitalization 56,8 M 62,6 M 63,1 M
Capi. / Sales 2020 3,72x
EV / Sales 2021 3,38x
Nbr of Employees 113
Free-Float 86,1%
More Financials
Company
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company is involved in the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases. The Company’s products include Catena and Raxone brands, which are primarily implemented in the symptomatic treatment of Leber's... 
Sector
Pharmaceuticals
Calendar
01/06Präsentation
More about the company
All news about SANTHERA PHARMACEUTICALS HOLDING AG
11/26SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
AQ
11/25SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
PU
11/25SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
AQ
11/25SANTHERA PHARMACEUTICALS : Completes Capital Increase for Financing Arrangements
AQ
11/25Santhera Completes Capital Increase for Financing Arrangements
GL
11/17SANTHERA PHARMACEUTICALS : ReveraGen Receives $3.3 Million NIH Commercialization..
PU
11/17SANTHERA PHARMACEUTICALS : ReveraGen Receives $3.3 Million NIH Commercialization..
PU
11/17SANTHERA PHARMACEUTICALS : ReveraGen Receives $3.3 Million NIH Commercialization..
AQ
11/10SANTHERA PHARMACEUTICALS : to Present at Jefferies Virtual London Healthcare Con..
PU
11/10SANTHERA PHARMACEUTICALS : to Present at Jefferies Virtual London Healthcare Con..
AQ
11/10SANTHERA PHARMACEUTICALS : to Present at Jefferies Virtual London Healthcare Con..
AQ
11/10Santhera to Present at Jefferies Virtual London Healthcare Conference
GL
11/02SANTHERA PHARMACEUTICALS : Implements Reorganization and Secures Financing to Ad..
AQ
11/02SANTHERA PHARMACEUTICALS : Implements Reorganization and Secures Financing to Ad..
AQ
11/02Santhera Implements Reorganization and Secures Financing to Advance Vamorolon..
GL
More news
News in other languages on SANTHERA PHARMACEUTICALS HOLDING AG
11/25Santhera finalise son augmentation de capital
11/25Santhera mit Kapitalerhöhung für Finanzierungsvereinbarungen
11/25SANTHERA PHARMACEUTICALS : vollzieht Kapitalerhöhung für Finanzierungsvereinbaru..
11/17Corr le partenaire de Santhera, ReveraGen Biopharma, obtient une subvention
11/17KORR : Santhera-Partner ReveraGen Biopharma erhält Mittel von US-Behörde
More news
Chart SANTHERA PHARMACEUTICALS HOLDING AG
Duration : Period :
Santhera Pharmaceuticals Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANTHERA PHARMACEUTICALS HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Average target price 3,00 CHF
Last Close Price 2,99 CHF
Spread / Highest target 0,33%
Spread / Average Target 0,33%
Spread / Lowest Target 0,33%
EPS Revisions
Managers
NameTitle
Dario Eklund Chief Executive Officer
Elmar J. Schnee Chairman
Andrew P. Smith Chief Financial Officer
Kristina Sjöblom Nygren Chief Medical Officer, EVP & Head-Development
Thomas Meier Director
Sector and Competitors